Feld Jordan J, Ocama Ponsiano, Ronald Allan
Infectious Disease Clinic, Department of Medicine, Mulago Hospital, Kampala, Uganda.
Antivir Ther. 2005;10(8):953-65.
As access to antiretroviral therapy improves across the African continent, liver disease is emerging as an important cause of morbidity and mortality among HIV-infected individuals. Although coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV), along with highly active antiretroviral therapy (HAART)-induced hepatotoxicity appear to be the major causes of liver disease in this population, other diseases endemic to Africa with hepatic manifestations are influenced by HIV infection as well. In this review we present the available data on liver disease in HIV-infected populations in Africa and discuss relevant data from the rest of the world. In addition, we highlight important areas for further study.
随着抗逆转录病毒疗法在非洲大陆的可及性不断提高，肝脏疾病正成为艾滋病毒感染者发病和死亡的重要原因。虽然乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）合并感染以及高效抗逆转录病毒疗法（HAART）引起的肝毒性似乎是该人群肝脏疾病的主要原因，但非洲其他有肝脏表现的地方病也受到艾滋病毒感染的影响。在本综述中，我们展示了非洲艾滋病毒感染人群肝脏疾病的现有数据，并讨论了来自世界其他地区的相关数据。此外，我们强调了需要进一步研究的重要领域。
